Analysts Set Trillium Therapeutics Inc. Price Target $22.40 Analysts Set Trillium Therapeutics Inc. (TRIL) Price Target at $22.40
Posted by Joseph Griffin on Nov 14th, 2016 // No Comments
Trillium Therapeutics Inc. (NASDAQ:TRIL) has received an average recommendation of “Buy” from the seven brokerages that are presently covering the firm. Seven equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $22.40.
TRIL has been the subject of a number of recent research reports. Zacks Investment Research cut shares of Trillium Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 19th. Ladenburg Thalmann initiated coverage on shares of Trillium Therapeutics in a research note on Wednesday, August 3rd. They issued a “buy” rating and a $18.00 price objective for the company. Leerink Swann reissued an “outperform” rating and issued a $20.00 price objective on shares of Trillium Therapeutics in a research note on Monday, August 15th. BTIG Research initiated coverage on shares of Trillium Therapeutics in a research note on Thursday, October 6th. They issued a “buy” rating and a $21.00 price objective for the company. Finally, Cowen and Company reissued a “buy” rating on shares of Trillium Therapeutics in a research note on Thursday, November 3rd.
Several institutional investors have recently added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC purchased a new position in Trillium Therapeutics during the first quarter worth approximately $100,000. Creative Planning raised its stake in shares of Trillium Therapeutics by 37.3% in the third quarter. Creative Planning now owns 8,100 shares of the company’s stock worth $120,000 after buying an additional 2,200 shares during the last quarter. K2 Principal Fund L.P. bought a new stake in shares of Trillium Therapeutics during the second quarter worth $131,000. Wells Fargo & Company MN raised its stake in shares of Trillium Therapeutics by 1,080.0% in the third quarter. Wells Fargo & Company MN now owns 11,800 shares of the company’s stock worth $175,000 after buying an additional 10,800 shares during the last quarter. Finally, New Leaf Venture Partners L.L.C. bought a new stake in shares of Trillium Therapeutics during the second quarter worth $725,000. 41.24% of the stock is owned by hedge funds and other institutional investors.
Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at 8.00 on Friday. The firm has a 50-day moving average of $13.55 and a 200-day moving average of $11.48. Trillium Therapeutics has a one year low of $6.62 and a one year high of $17.70. The stock’s market cap is $62.51 million.
https://www.tickerreport.com/banking-finance/2267111/analysts-set-trillium-therapeutics-inc-tril-price-target-at-22-40.html